I wonder whether Peter Doshi apreciates that employing a measured
approach to such events could result in frustrating pharmaceutical
industry growth targets? We might get a different view of all this if we
looked at the financial models rather than the medical ones.
For instance, a report from PriceWaterhouseCoopers last year
envisaged a pharmaceutical industry in 2020 which is more than double the
size of the present global industry, in which the primary shift of focus
is from "treatment to prevention". This is a lot of prevention.
Here are two other interesting financial reports: 'Kids' vaccine
market set to quadruple' from November 2007 which projects a
quadrupling of the juvenile vaccine market over the period of a decade,
and the more recent 'New report forecasts more than doubling of vaccine
sales by 2014'.
Presently in the UK we already administer 25 vaccines by 13 months of
age so you might have thought that the room for expansion was limited.
I believe there is an ethical imperative at this juncture to stand
back and ask what is happening, and why?
 PriceWaterhouseCooper, 'Pharma2020: Which path will you take?'
Competing interests: No competing interests